In Re Glumetza Antitrust Litigation

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

In re No. C 19-05822 WHA GLUMETZA ANTITRUST No. C 19-06138 WHA LITIGATION. No. C 19-06839 WHA No. C 19-07843 WHA No. C 19-08155 WHA No. C 20-01198 WHA This Document Relates to: No. C 20-05251 WHA 12 DIRECT PURCHASER ACTIONS. (Consolidated)

ORDER CERTIFYING CLASS

14 INTRODUCTION In this antitrust action arising from an alleged reverse-payment settlement of a patent infringement suit between brand and generic marketers of the diabetes drug Glumetza, direct purchaser plaintiffs move for class certification. Common issues predominate, the putative class’s market-impact and damages models adequately reflect the theory of liability, and any assumptions underlying the model either go to the heart of the merits or can be modified to account for a range of jury determinations. A class is CERTIFIED. STATEMENT A prior order details this…